UBS On-Air: Paul Donovan Daily Audio 'Tariff time?'
Per the full note source, UBS Chief Economist Paul Donovan downplays the near-term market impact of Trump's proposed pharma tariffs, arguing that the delayed 2027–2029 implementation and likely legal challenges reduce the probability-weight markets assign to them. Donovan's main focus is on the expiration of interim 10% tariffs this Friday, which he sees as limited in inflation impact since most pass-through was already absorbed via the unlawful tariff regime. The desk signals that USD direction remains driven more by the affordability crisis and general trade policy noise rather than this specific headline, with no overt currency call.
What the desk is arguing
UBS Chief Economist Paul Donovan dismisses the market significance of President Trump's proposed 100–200% tariffs on imported generic pharmaceuticals, scheduled for August 2027 and 2029. Per the full note source, the desk frames these as low-probability events given the extended timeline and expected legal hurdles, advising investors not to assign a "100% weighting" to their implementation.
Donovan's primary concern is the imminent expiry of interim 10% tariffs this Friday, which the administration plans to replace with approximately 10% tariffs on new products. He argues that since unlawful tariffs were already passed through to consumers, the new levies will only affect prices for previously untariffed goods, limiting the inflation shock.
The counterfactual the desk implicitly rejects is that these pharma tariffs could trigger a broad repricing of USD risk premia or a shift in Fed expectations. Instead, Donovan anchors the debate in the ongoing affordability crisis, suggesting consumer price pressures remain the true macro focus.
Key takeaways
- 01Trump's pharma tariff proposal (100% in Aug 2027, 200% in Aug 2029) is viewed as low probability by UBS due to timeline and legal uncertainty.
- 02Expiring interim tariffs this Friday are the more immediate focus; new replacement tariffs likely limited in inflation pass-through.
- 03No USD-specific trade recommendation; the desk flags the affordability crisis as the dominant macro theme.
- 04Pharma tariffs add risk to USD/CNH and emerging market FX exposed to US imports, but implementation is too distant to trade.
Market implications
Watch USD/CNH and other Asia FX on Friday as markets react to the tariff replacement details. Any surprise expansion of product coverage could trigger a risk-off move, but the default expectation is a muted dollar response given the narrow scope. The delayed pharma tariffs may be a long-tail risk for USD shorts, but no near-term catalyst is identified.
Risks to this view
If the administration accelerates the pharma tariff timeline or applies them retroactively, the USD could see a knee-jerk rally on safe-haven flows. Additionally, any broader 10% tariff on all imports not previously covered would reignite inflation fears, forcing markets to reprice Fed tightening and boosting the dollar. The desk's view is invalidated if legal challenges fail and tariffs are enacted ahead of schedule.
Good morning, this is Paul Donovan, Chief Economist at UBS Global Wealth Management. It's 4.30 in the morning London time on Wednesday the 22nd of July. Tariffs seem to be the focus in Washington DC, even as the affordability crisis remains the focus elsewhere in the country.
US President Trump has said that US consumers of generic pharmaceuticals imported into the United States would be facing a 100% tariff from August 2027 and 200% from August 2029. US healthcare costs are significantly higher than most of the developed world, while the outcomes are generally worse, and this would in theory add to those costs. Using the latest World Health Organization data, the US already spends 16.7% of GDP on healthcare.
Most of developed Europe is in a 10-12% range, despite having older populations. Markets will pay some attention to this latest potential price increase, given the severity of the cost US consumers would be being asked to pay. However, it is also worth reflecting that these tariffs would be imposed late in Trump's term of office, and they may also be subject to legal challenges, so investors are not likely to give a 100% weighting to the probability of them being imposed.
Markets are also waiting for the announcement of the approximately 10% tariffs to replace the interim 10% tariffs due to expire on Friday, that in turn replace the unlawful tariffs. The economic impact of these new tariffs is limited, at least as far as inflation goes. The unlawful tariffs were already passed through to US consumers, and the consumer price implications of those has generally not been reversed in anticipation of exactly the tariffs that are happening now.
Only where brand new products are to be tariffed, not covered by previous tariff initiatives, will US consumer prices likely increase. It is theoretically possible that some companies might try to use the new tariffs as an excuse to sneak in some form of price increases, but with the affordability crisis very much in focus, it seems unlikely that consumers would tolerate such profit-led price initiatives. UK inflation data is of course unaffected by tariffs, and today's release is expected to show a moderate slowing in the pace of price increase.
This is June data, and it is in July that the electricity price increases are likely to hit, owing to the weird way the UK sets prices in its electricity market. The government has announced an intention of removing the 5% value-added tax from the cost of electricity as from October, and that can be considered something of a gesture. The measure is as yet unfunded, although it is not a hugely expensive measure, stretching credibility a certain amount, the very modest reduction in inflation rates arising from this would likely lower the cost of funding the sizeable inflation-linked government bond market.
Sources & References
How we cover this story